The investigational product (IP) is ‘multi-virus-specific T cells TI1’, and consists of T cells targeting cytomegalovirus (CMV), Epstein–Barr virus (EBV), BK polyomavirus (BKV) and adenovirus (AdV). I Clinical Trials
2 recruitingIntervention
Phase 12
Showing 1–2 of 2 trials
Recruiting
Phase 1
Virus-specific T cell therapy for transplant recipients
recurrent or drug-resistant viral infectionViral reactivationBK polyomavirus+1 more
QIMR Berghofer Medical Research Institute25 enrolled4 locationsACTRN12621000323820
Recruiting
Phase 1
Phase I trial of multi-virus-specific T cells for paediatric haploidentical -stem cell transplant recipients
Haplo-identical haematopoietic stem cell transplantation
QIMR Berghofer Medical Research Institute20 enrolled1 locationACTRN12620000141943